Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Novo Nordisk A/S
Study ID
NCT02863419
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • semaglutide — DRUG
    Oral semaglutide once-daily.
  • liraglutide — DRUG
    Subcutaneous (s.c.) injection once-daily.
  • placebo — DRUG
    Placebo once-daily.

Study Details

This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus.

Key Dates

Start date
Aug 10, 2016
Status verified
Jul 2022
Primary completion
Aug 19, 2017
Completion
Mar 30, 2018

Study Design

Enrollment
711 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Oral Semaglutide
  • Active Comparator: Liraglutide
  • Placebo Comparator: Placebo

Primary Outcome Measure

Change in HbA1c (Week 26) [ Time Frame: Week 0, week 26 ]

Locations (40)

FacilityCityStateZIPSite coordinators
Novo Nordisk Investigational SiteBirminghamAlabama35222-
Novo Nordisk Investigational SiteLos AlamitosCalifornia90720-
Novo Nordisk Investigational SiteSan DiegoCalifornia92111-
Novo Nordisk Investigational SiteDenverColorado80246-
Novo Nordisk Investigational SiteHallandaleFlorida33009-
Novo Nordisk Investigational SiteJacksonvilleFlorida32256-
Novo Nordisk Investigational SiteMiamiFlorida33155-
Novo Nordisk Investigational SiteOcalaFlorida34470-
Novo Nordisk Investigational SiteOrlandoFlorida32801-
Novo Nordisk Investigational SiteOrlandoFlorida32804-
Novo Nordisk Investigational SiteOrmond BeachFlorida32174-6302-
Novo Nordisk Investigational SiteSt. PetersburgFlorida33713-
Novo Nordisk Investigational SiteWest Palm BeachFlorida33401-
Novo Nordisk Investigational SitePeoriaIllinois61603-
Novo Nordisk Investigational SiteTopekaKansas66606-
Novo Nordisk Investigational SiteSlidellLouisiana70461-4231-
Novo Nordisk Investigational SiteButteMontana59701-
Novo Nordisk Investigational SiteLebanonNew Hampshire03756-
Novo Nordisk Investigational SiteTeaneckNew Jersey07666-
Novo Nordisk Investigational SiteAlbanyNew York12203-
Novo Nordisk Investigational SiteMineolaNew York11501-
Novo Nordisk Investigational SiteGreensboroNorth Carolina27408-
Novo Nordisk Investigational SiteMorgantonNorth Carolina28655-
Novo Nordisk Investigational SiteWilmingtonNorth Carolina28401-
Novo Nordisk Investigational SiteDublinOhio43016-
Novo Nordisk Investigational SiteMaumeeOhio43537-
Novo Nordisk Investigational SiteNormanOklahoma73069-
Novo Nordisk Investigational SiteMcMurrayPennsylvania15317-
Novo Nordisk Investigational SiteSummervilleSouth Carolina29485-
Novo Nordisk Investigational SiteBristolTennessee37620-7352-
Novo Nordisk Investigational SiteArlingtonTexas76012-4637-
Novo Nordisk Investigational SiteDallasTexas75230-
Novo Nordisk Investigational SiteDallasTexas75390-9302-
Novo Nordisk Investigational SiteHoustonTexas77004-7000-
Novo Nordisk Investigational SiteNorth Richland HillsTexas76180-
Novo Nordisk Investigational SiteSan AntonioTexas78229-
Novo Nordisk Investigational SiteSan AntonioTexas78249-
Novo Nordisk Investigational SiteNewport NewsVirginia23606-
Novo Nordisk Investigational SiteRichmondVirginia23219-
Novo Nordisk Investigational SiteVirginia BeachVirginia23454-

Find similar trials in Birmingham, AL

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Novo Nordisk Investigational Site· Birmingham, ALNovo Nordisk Investigational Site· Los Alamitos, CANovo Nordisk Investigational Site· San Diego, CANovo Nordisk Investigational Site· Denver, CONovo Nordisk Investigational Site· Hallandale, FLNovo Nordisk Investigational Site· Jacksonville, FL

Related Studies